La cadena de opciones muestra datos clave de las opciones de acciones de Contineum Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Contineum Therapeutics..

Contineum Therapeutics (NASDAQ:CTNM) Bolsa, Cadena de Opciones

Contineum Therapeutics

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Contineum Therapeutics, Inc. - Common stock

Contineum Therapeutics Inc

CHINA TREASURES NEW MATLS by CHINA TREASURES NEW MATLS GROUP LTD

China Treasures New Materials Group Ltd

Norwegian Cruise Line Holdings &nbsp;and NCL Corporation Ltd., a subsidiary of the Company ("NCLC"), announce that NCLC has entered into individually negotiated note exchange agreements with certain existing holders (the "Holders") of NCLC's 5.375% Exchangeable Senior Notes due 2025 (the "2025 Notes"), pursuant to which NCLC and the Holders have agreed to exchange (the "Exchange") $285,425,000 in aggregate principal amount of the Holders' 2025 Notes for (i) $285,425,000 in aggregate principal amount of NCLC's newly issued 0.875% Exchangeable Senior Notes due 2030 (the "2030 Notes") and (ii) an aggregate cash payment (the "Cash Payment") of $51,624,820, plus accrued and unpaid interest on the 2025 Notes to be exchanged to, but excluding, the closing date of the Exchange. The Cash Payment will be equal to the proceeds from the concurrent Equity Offering, as described below, and represents the remainder of NCLC's exchange obligation in excess of the aggregate principal amount of the 2025 Notes to be exchanged.
Concurrently, the Company announces a registered direct offering of 2,708,533 ordinary shares to the Holders at a price of $19.06 per share (the "Equity Offering" and together with the Exchange, the "Transactions"). The Company expects to use the proceeds from the Equity Offering to make the Cash Payment.

News

NCLH

NCLH To Cut Fully Diluted Share Count By 12.5M Following Note Exchange And Equity Sale

Telsey Advisory Group analyst Dana Telsey maintains PVH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) with a Outperform and maintains $90 price target.

Price Target

Analyst Ratings

Telsey Advisory Group Maintains Outperform on PVH, Maintains $90 Price Target

PROP

Prairie Operating Co. Launches 11-Well Development Program At Rusch Pad In Colorado's DJ Basin

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Aquestive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQST#NASDAQ">AQST</a>) with a Buy and maintains $10 price target.

Reiteration

AQST

HC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $10 Price Target

CRGO

Freightos Expands With Air Europa Partnership, Enhancing Digital Freight Booking Across Spain-Latin America Routes

Telsey Advisory Group analyst Dana Telsey maintains Levi Strauss (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) with a Outperform and maintains $23 price target.

LEVI

Telsey Advisory Group Maintains Outperform on Levi Strauss, Maintains $23 Price Target

Financial Outlook
BlackBerry is providing the following guidance for the first fiscal quarter and the full fiscal year 2026 (ending February 28, 2026).
<figure class="table"> 
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>Q1 FY26</td>
<td>Full fiscal year FY26</td>
</tr>
<tr>
<td>Total BlackBerry revenue:</td>
<td>$107 - $115 million</td>
<td>$504 - $534 million</td>
</tr>
<tr>
<td>QNX revenue:</td>
<td>$51 - $55 million</td>
<td>$250 - $270 million</td>
</tr>
<tr>
<td>Secure Communications revenue:</td>
<td>$50 - $54 million</td>
<td>$230 - $240 million</td>
</tr>
<tr>
<td>Licensing revenue:</td>
<td>Approximately $6 million</td>
<td>Approximately $24 million</td>
</tr>
<tr>
<td>QNX segment adjusted EBITDA:</td>
<td>$2 - $6 million</td>
<td>$55 - $60 million</td>
</tr>
<tr>
<td>Secure Communications segment</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>adjusted EBITDA:</td>
<td>$3 - $6 million</td>
<td>$34 - $44 million</td>
</tr>
<tr>
<td>Licensing segment adjusted EBITDA:</td>
<td>Approximately $5 million</td>
<td>Approximately $20 million</td>
</tr>
<tr>
<td>Adjusted Corporate Costs:</td>
<td>Approximately $10 million</td>
<td>Approximately $40 million</td>
</tr>
<tr>
<td>Total Company adjusted EBITDA:</td>
<td>Breakeven - $7 million</td>
<td>$69 - $84 million</td>
</tr>
<tr>
<td>Non-GAAP basic EPS:</td>
<td>($0.01) - Breakeven</td>
<td>$0.08 - $0.10</td>
</tr>
<tr>
<td>Operating cash flow (usage)</td>
<td>($20) - ($30) million</td>
<td>Approximately $35 million</td>
</tr>
</tbody>
</table>
</figure>

Guidance

BlackBerry Now Expects FY26 Total Revenue Of $504M-$534M Vs $546.34M Est, Adj EPS Of $0.08-$0.10 Vs $0.10 Est

HC Wainwright &amp; Co. analyst Matthew Caufield maintains Mineralys Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLYS#NASDAQ">MLYS</a>) with a Buy and raises the price target from $30 to $42.

MLYS

HC Wainwright & Co. Maintains Buy on Mineralys Therapeutics, Raises Price Target to $42

Telsey Advisory Group analyst Dana Telsey maintains Macy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) with a Market Perform and maintains $15 price target.

Telsey Advisory Group Maintains Market Perform on Macy's, Maintains $15 Price Target

As a result, the company expects first quarter 2025 Adjusted Profit Before Tax&nbsp;in a range of $92.3 to $97.3 million (Q1 2024: $67.7 million).
 &nbsp;

Marex Group Expects Q1 Revenues $449.3M - $464.3M, Est $421.573M; Adj EPS Of $0.88 - $0.93, Est $0.77

BRKR

Bruker Announces Introduction Of d-DNP Polarizer For MRI Research And For Dynamic Nuclear Polarization Liquids NMR

HC Wainwright &amp; Co. analyst Matthew Caufield reiterates Surrozen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRZN#NASDAQ">SRZN</a>) with a Buy and maintains $32 price target.

SRZN

HC Wainwright & Co. Reiterates Buy on Surrozen, Maintains $32 Price Target

Republic National Distribution Company opens new distribution channels in six states including California, one of the largest markets in the U.S.

Innovation Beverage Group Expands U.S. Reach With Republic National Distribution Company Distribution Deal

Ziff Davis Acquires theSkimm And Maxroll In Q1 To Expand Global Reach And Product Portfolio

HC Wainwright &amp; Co. analyst Mitchell Kapoor upgrades Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from Sell to Neutral and maintains the price target from $75 to $75.

Upgrades

SRPT

HC Wainwright & Co. Upgrades Sarepta Therapeutics to Neutral, Maintains Price Target to $75

BlackBerry Expects Q1 Total Revenue Of $107M-$115M Vs $127.99M Est, Adj EPS Of $(0.01)-Breakeven Vs $0.01 Est

DASH

Domino's Partners With DoorDash For Nationwide U.S. Launch In May 2025, Expanding To Canada Later

D. Boral Capital analyst Jesse Sobelson maintains PEDEVCO (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PED#AMEX">PED</a>) with a Buy and maintains $1.5 price target.

D. Boral Capital Maintains Buy on PEDEVCO, Maintains $1.5 Price Target

Renews highly coveted and valuable hockey rights long term Will deliver more national games and fewer blackouts to hockey fans Rogers is proud to remain the home of NHL&nbsp;hockey

NHL And Rogers Extend National Media Rights Partnership With 12-Year, $11B Agreement

Quest Diagnostics Launches New HPV Screening Solution To Enhance Cervical Cancer Risk Detection

Press Releases

Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain

Comments

Contineum Therapeutics

Contineum Therapeutics (CTNM) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL